| Date issued | Product | Safety information |
| 17/03/41 |
FEGONA®
|
FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception . CLICK HERE |
| 22/02/41 |
Zofran®
|
Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron) . CLICK HERE |
| 20/01/41 |
Methotrexate "Ebewe”
|
Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases CLICK HERE |
| 12/01/41 |
Roaccutne
|
Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE |
| 25/12/40 |
soliqua (lixisenatide /insuline glargin) soliqua
|
(lixisenatide /insuline glargin): Important information on dosing.CLICK HERE |
| 25/12/40 |
Advaquin ( levofloxacin)
|
Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE |
| 07/12/40 |
Gilenya (fingolimod)
|
Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE |
| 28/10/40 |
Darzalex (Daratumumab)
|
Darzalex (Daratumumab): New identified risk of hepatitis B reactivation.CLICK HERE |
| 24/10/40 |
Lemtrada® Alemtuzumab
|
|
| 09/10/40 |
Apixaban, Edoxaban, Dabigatran and Rivaroxaban
|
Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban.CLICK HERE |